Truist Securities raises PT on Palvella Therapeutics on lead drug potential

Palvella Therapeutics

02/10/2025 16:51

** Truist Securities raises PT on drug developer Palvella Therapeutics PVLA.O to $80 from $56

** Brokerage sees potential for Palvella's lead drug candidate, QTORIN rapamycin, being tested in a late-stage trial for microcystic lymphatic malformations, a rare disease that causes fluid-filled cysts on the skin

** Truist sees commercial opportunity for the drug if trials succeed and new indications progress

** The PT raise also reflects PVLA's plans around a potential capital raise -brokerage

** All 13 analysts covering the stock rate "buy" or higher; median PT is $70 - data compiled by LSEG

** Including session's move, PVLA stock up ~429% YTD

 (Reporting by Anuj T in Bengaluru)

 ((anuj.t@thomsonreuters.com))